Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Interim Results

28 Sep 2005 10:01

ISIS Resources PLC28 September 2005 ISIS RESOURCES PLC Company No. 5375156 Interim Financial Reportfor the period ended 30 June 2005 Chairman's Statement 1 Independent Review Report 2 Profit and Loss Account 3 Balance Sheet 4 Cash Flow Report 5 Notes to the Interim Report 6-7 DIRECTORS, SECRETARY AND ADVISERS Directors Broker Craig Ian Burton (Chairman) Westhouse Securities LLP Josef El-Raghy Clements House Stuart Bottomley 14-18 Gresham Street London EC2V 7NN Registered Office and Directors' business address Nominated Adviser Adderbury Hill Barn RFC Corporate Finance Ltd Milton Road Level 8 Adderbury 250 St Georges Terrace Oxon OX17 3HN Perth WA 6000 Australia Secretary Auditors Katie Macdonald Keen EK & Co 2003 Ltd 12B Talisman Business Centre Bicester Oxon OX26 6HR Solicitors to the Company Principal Banker Watson, Farley & Williams Bankwest 15 Appold Street 1215 Hay Street, West Perth London EC2A 2HB Western Australia 6005 Registrars Computershare Investor Services PLC PO Box 82, The Pavilions Bridgewater Road Bristol BS99 7NH Phone: 0870 702 0000 ISIS RESOURCES PLC CHAIRMAN'S STATEMENT Welcome to the first Interim Report for Isis Resources Plc. Since your Companylisted on the AIM on March 30 this year, the Directors have reviewed a number ofinvestment and acquisition opportunities. At 30 June 2005 the Company had US$1.8m cash at bank. The Directors have focused on investment and acquisition opportunities in thenatural resources, mining service and technology sectors that would be suitableto the Company and shareholders. A potential investment may be either listed orunlisted and may be in companies, joint ventures, or direct ownership ofprojects. The Directors have continued to evaluate appropriate investmentopportunities for the Company from Africa, Europe and Australia. The Company currently has an experienced Board of three Directors who betweenthem have considerable investment and commercial expertise. The composition ofthe Board will be reviewed on a regular basis to ensure it has the appropriatemix of skills necessary for the objectives of the Company. Josef El-Raghy is the Managing Director of Centamin Egypt, which is dual listedon the Australian Stock Exchange and AIM. Stuart Bottomley worked as aportfolio manager for over 20 years, firstly with the Target Group of UnitTrusts and subsequently with Fidelity International. For the last 12 years hehas acted as a consultant to a number of private and public companies, with agrowing emphasis on the mining industry. I have 12 years experience specialising in venture capital in the resourcessector. Over that period I have successfully co-founded nine public listednatural resource companies, with projects in a wide variety of commodities andgeographic locations. I am currently a director of four resources companieslisted on the ASX, one of which is dual listed on AIM. In closing, on behalf of the Board I would like to thank you for your financialsupport and the interest shown by you in the Company. Yours sincerely Craig Burton Chairman INDEPENDENT REVIEW REPORT TO ISIS RESOURCES PLC Introduction We have been instructed by the company to review the financial information forthe six months ended 30 June 2005 set out on pages 3 to 7 and we have read theother information contained in the interim report and considered whether itcontains any apparent misstatements or material inconsistencies with thefinancial information. Our responsibilities do not extend to any otherinformation. Directors' responsibilities The interim report including the financial information contained therein is theresponsibility of, and has been approved by, the directors. The Directors areresponsible for preparing the interim report in accordance with the AIM Ruleswhich require that the accounting policies and presentation applied to theinterim figures should be consistent with those applied in preparing thepreceding annual accounts except where any changes, and the reasons for them,are disclosed. Review work performed We conducted our review in accordance with guidance contained in Bulletin 1999/4"Review of Interim Financial Information" issued by the Auditing Practices Boardfor use in the United Kingdom. A review consists primarily of making enquiriesof management and applying analytical procedures to the financial informationand underlying financial data and based thereon, assessing whether theaccounting policies and presentation have been consistently applied unlessotherwise disclosed. A review excludes audit procedures such as test of controlsand verification of assets, liabilities and transactions. It is substantiallyless in scope than an audit performed in accordance with United Kingdom auditingstandards and therefore provides a lower level of assurance than an audit.Accordingly, we do not express an audit opinion on the financial information. Review conclusion On the basis of our review we are not aware of any material modifications thatshould be made to the financial information as presented for the six monthsended 30 June 2005. EK & Co 2003 Ltd Chartered Certified Accountants 12B Talisman Business Centre Bicester Oxon OX26 6HR ISIS RESOURCES PLC PROFIT AND LOSS ACCOUNT FOR THE PERIOD ENDED 30 JUNE 2005 6 months to 30 June 2005 Note (unaudited) US$ Administration Expenses (39,647)Operating Loss (39,647)Net interest 23,949Loss on ordinary activities before taxation (15,698)Tax on loss on ordinary activities -Loss on ordinary activities after taxation (15,698)Equity Minority Interests -Loss retained and transferred from reserves (15,698)Basic loss per share (cents per share) 2 (0.0508)Diluted loss per share (cents per share) 2 (0.0456) Statement of Total Recognised Gains and LossesLoss for the financial period (15,698)Exchange loss on foreign currency net inventories (19,287) Total recognised loss for the period (34,985) All transactions arise from continuing operations ISIS RESOURCES PLC BALANCE SHEET AS AT 30 JUNE 2005 At 30 June 2005 Note (unaudited) US$Fixed AssetsIntangible assets 0 0Current AssetsCash assets 1,806,430Receivables 3,556 1,809,986 Creditors: amounts falling due within one year (13,239) Net current assets 1,796,747 Total assets less current liabilities 1,796,747 Capital and reservesCalled up share capital 90,240Share premium account 1,741,492Profit and loss account (34,985)Shareholders Funds 5 1,796,747 ISIS RESOURCES PLC CASHFLOW STATEMENT FOR THE PERIOD ENDED 30 JUNE 2005 6 months to Note 30 June 2005 US$ Net cash inflow from operating activities 3 (49,251) Return on Investments and servicing of financeInterest received 23,949Net cash inflow from returns on Investments and servicing of 23,949finance Taxation - Capital expenditure and financial investmentPurchase of intangible fixed assets -Net cash outflow from capital expenditure and financial investment - Management of liquid resourcesShort term deposits - Net cash inflow before financing (25,302) FinancingIssue of shares 1,915,213Share issue costs (83,481)Net cash inflow from financing 1,831,732 Increase in cash 4 1,806,430 ISIS RESOURCES PLC NOTES TO THE INTERIM REPORT FOR THE PERIOD ENDED 30 JUNE 2005 1 Basis of Preparation of Financial Statements The interim financial information set out on pages 3 to 7 has been prepared onthe same basis and using the same accounting policies as will be applied inpreparing the accounts for the period ended 31 December 2005, the company'sfirst period end. The financial statements have been prepared under the historical cost convention Transactions of UK companies denominated in foreign currencies are translatedinto sterling at the rates ruling at the dates of the transactions. Amountsreceivable and payable in foreign currencies at the balance sheet date aretranslated at the rates ruling at that date. The financial information for the 6 months ended 30 June 2005 is unaudited. Inthe opinion of the directors the financial information for these periods fairlypresents the financial position, results of operations and cash flows for thoseperiods and conform with generally accept account principles. This is the first interim report for Isis Resources for the period fromincorporation 24 February 2005 to 30 June 2005. The functional currency of the Group is United States dollars (US$). Thisrepresents the currency of the primary economic environment in which the Groupoperates. The Interim report has been prepared in US$. 2 Loss Per Share The calculation of the loss per share is based on a loss of $15,698 to 30 June2005 and the weighted average number of ordinary shares outstanding of30,920,635 at 30 June 2005. The diluted earnings per share is based on aweighted average number of shares outstanding of 34,412,699 and the loss pershare presented. 3 Net Cash Outflow from Operating Activities 6 months to 30 June 2005 (unaudited) US$Operating loss (39,647)Increase in debtors (3,556)Increase in creditors 13,239Foreign exchange loss (19,287) Net cash inflow from operating activities (49,251) 4 Reconciliation of Net Cash Flows to Movement in Net Funds 6 months to 30 June 2005 (unaudited) US$ Increase in cash in the period 1,806,430Cash (outflow)/inflow from financing - short term - 1,806,430 Net funds at beginning of period -Net funds at end of period 1,806,430 5 Reconciliation of Movements in Shareholders Funds Loss for the period (15,698)Exchange loss on foreign currency net investments (19,287)New share capital subscribed 1,915,213Costs of Capital (83,481)Net increase in shareholders funds 1,796,747 6 Publication of Non-statutory Accounts The financial information set out in this interim report does not constitutestatutory accounts as defined in section 240 of the Companies Act 1985. Theauditors' report on these financial statements was unqualified and did notcontain a statement under Section 237(2) of the Companies Act 1985 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
10th Jan 202011:00 pmGNWVerona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy
7th Jan 20207:00 amGNWVerona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations
28th Nov 201910:25 amGNWHolding(s) in Company TR-1: Standard form for notification of major holdings
27th Nov 20197:00 amGNWVerona Pharma plc: Grant of Options to PDMR
18th Nov 20197:00 amGNWVerona Pharma plc: PDMR Dealing – Purchase by Chairman
14th Nov 20197:00 amGNWVerona Pharma plc: PDMR Dealing – Purchase by Chairman
13th Nov 20197:00 amGNWVerona Pharma to Present at Jefferies 2019 London Healthcare Conference
11th Nov 20197:00 amGNWVerona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New York
5th Nov 20197:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019
29th Oct 20197:00 amGNWVerona Pharma to Announce Financial Results for the Three and Nine Months Ended September 30, 2019 and Provide Clinical Development Update
17th Oct 20197:00 amGNWVerona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD
15th Oct 20197:00 amGNWVerona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
19th Sep 20197:00 amGNWVerona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
9th Sep 20192:33 pmGNWHolding(s) in Company TR-1: Standard form for notification of major holdings
3rd Sep 20197:00 amGNWVerona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
9th Aug 20199:35 amGNWVerona Pharma plc: PDMR Dealing
6th Aug 20197:00 amGNWVerona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019
5th Aug 20197:00 amGNWVerona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
30th Jul 20197:00 amGNWVerona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development Update
24th Jul 20197:00 amGNWVerona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare Conference
25th Jun 20197:00 amGNWVerona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine
4th Jun 20197:00 amGNWVerona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
30th May 20197:00 amGNWVerona Pharma to Present at Jefferies 2019 Global Healthcare Conference
29th May 201911:07 amRNSPDMR Dealing
20th May 20193:15 pmGNWVerona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
7th May 201912:51 pmGNWResult of AGM
7th May 20197:00 amGNWVerona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
7th May 20197:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
2nd May 201912:00 pmGNWVerona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
1st May 20197:00 amGNWVerona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker
1st May 20197:00 amGNWVerona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update
25th Apr 201912:07 pmGNWVerona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019
4th Apr 20197:00 amGNWGrant of Options and RSUs and PDMR Dealings
26th Mar 20197:00 amGNWVerona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
25th Mar 20197:00 amGNWPDMR Dealing
22nd Mar 20194:00 pmGNW2018 Annual Report and Accounts and Notice of AGM 
11th Mar 20199:48 amGNWPDMR Dealing
7th Mar 20198:14 amGNWPDMR Dealing
5th Mar 20199:48 amGNWPDMR Dealing
4th Mar 20197:00 amGNWVerona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD
28th Feb 20197:00 amGNWVerona Pharma to Present at Cowen and Company 39th Annual Health Care Conference
26th Feb 20197:00 amGNWVerona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update
20th Feb 20197:00 amGNWVerona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update
4th Feb 20197:00 amGNWVerona Pharma to Present at Upcoming Investor Conferences
14th Jan 20197:00 amGNWVerona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
9th Jan 20191:00 pmGNWVerona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554
17th Dec 20185:20 pmGNWVerona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
17th Dec 20187:00 amGNWVerona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
6th Nov 20187:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018
31st Oct 20187:00 amGNWVerona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.